Gsk plc
GSK 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上
GSK 近期報酬表現
2.73%
Gsk plc
2.06%
同產業平均
-0.34%
S&P500
與 GSK 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SNY | Sanofi s.a. | 3 分 | 3 分 | 4 分 | 2 分 | 5 分 | |
HLN | Haleon plc - adr | - | 3 分 | 4 分 | 1 分 | 1 分 | |
JNJ | Johnson & johnson | 2 分 | 2 分 | 1 分 | 3 分 | 5 分 | |
LXEO | Lexeo therapeutics inc | - | 2 分 | 2 分 | 3 分 | 1 分 | |
AZN | Astrazeneca plc | 4 分 | 5 分 | 4 分 | 2 分 | 5 分 |
- SNY Sanofi s.a.價值 3 分趨勢 3 分波段 4 分籌碼 2 分股利 5 分查看更多
GSK 公司資訊
GSK plc is a global biopharma company. The Company's segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.